Eoin Gogarty

Eoin Gogarty

Auto-generated profile, based on publicly available information

Eoin Gogarty

Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2024 in medRxiv
Verified
Preprint
Open access
PDF file
MLMaximin Lange
Maximin Lange
MMMeredith Martyn
Meredith Martyn
EGEoin Gogarty
Eoin Gogarty
PBPhilip Braude
Philip Braude
FFFeras Fayez
Feras Fayez
BCBen Carter
Ben Carter
We will develop a novel approach to drug repurposing, utilising Natural Language Processing (NLP) and Literature Based Discovery (LBD) techniques. This will present a simplified, accessible drug repurposing pipeline using Word2Vec embeddings trained on PubMed abstracts to identify potential new medications to be repurposed. We present this approach in the context of antipsychotics, but it could be repeated for any available medication. The research is structured in three stages: Identification of candidate medications using Word2Vec algorithm trained on scientific literature. Empirical testing of identified candidates using a large hospital dataset to explore protective effects against disease onset. Validation of findings using a second, independent dataset to assess generalizability. This method addresses limitations in current machine learning-based drug repurposing approaches, including lack of external validation and limited accessibility. By leveraging Word2Vec’s ability to capture semantic relationships between words, the study aims to uncover hidden connections in medical literature that may lead to novel therapeutic discoveries. The protocol emphasizes transparency and reproducibility, utilizing publicly available electronic health record (EHR) databases for validation. This approach allows for tangible results even for researchers with limited machine learning expertise, bridging the gap between biomedical and information systems communities.

20 August 2025 in Online Journal of Public Health Informatics
Verified
Journal Article
Open access
LHLiliana Hidalgo-Padilla
Liliana Hidalgo-Padilla
MDMassar Dabbous
Massar Dabbous
KHKristoffer Halvorsrud
Kristoffer Halvorsrud
TBThomas Beaney
Thomas Beaney
GGGideon Gideon
Gideon Gideon
MCMariana Pinto da Costa
Mariana Pinto da Costa
The COVID-19 pandemic accelerated the adoption of remote consultations across health care, requiring rapid adjustments in service delivery. Consequently, there is an urgent need to understand the impact of remote consultations on health pathways. This viewpoint paper explores key challenges in data sources in England that hinder research on the impact of remote consultations on health outcomes. Based on our experience conducting research on this topic, we present variations in observational study findings and their validity, considering differences in population characteristics and data sources. We provide recommendations to enhance data quality for future research, including improvements in data recording platforms and strengthened structures for linking primary and secondary care electronic health records.

19 August 2026 in Interventional Cardiology: Reviews, Research, Resources
Verified
Journal Article
Open access
PDF file
EGEoin Gogarty
Eoin Gogarty
ISIsabelle Sweeney
Isabelle Sweeney
BTBrian Tam To
Brian Tam To
JWJack Wu
Jack Wu
ASAjay M Shah
Ajay M Shah
KOKevin O'Gallagher
Kevin O'Gallagher
Background: People with severe mental illness (SMI) experience significant health disparities, including in cardiovascular care. This study used natural language processing (NLP), an artificial intelligence method, to investigate care pathways for SMI patients within a highly protocolised urban primary angioplasty network for ST-elevation MI (STEMI). Methods: This cohort study used NLP to extract SMI diagnoses and clinical data from free-text electronic health records, including STEMI and non-STEMI audit data. Primary outcomes included 28-day and 1-year mortality, with secondary outcomes examining pathway performance metrics and procedural data. Exploratory outcomes assessed presenting symptoms and comorbidities. Results: A total of 2,292 adults presented with first-time STEMI from 2012–2019, of whom 51 (2.2%) had recorded SMI diagnoses. No significant differences were found in mortality between SMI and non-SMI patients at 28-day and 1-year, although a non-significant trend toward higher crude mortality in SMI patients emerged at 3 years (23.5% versus 16.1%; p=0.152). Procedure metrics and timings were similar between groups. SMI patients were more likely to have presented with cardiac arrest (adjusted OR 2.48; 95% CI [1.18–5.22]; p=0.017) and had higher rates of chronic obstructive pulmonary disease (adjusted OR 2.20; 95% CI [1.00–4.83]; p=0.049). Percutaneous coronary intervention rates in SMI patients with a non-STEMI were less than their representation in the overall non-STEMI population (2.2% versus 3.3%; p=0.042). Conclusion: Highly protocolised STEMI pathways appear to provide equitable acute care for patients with SMI without excess short-term mortality. However, potential disparities emerge in longer-term outcomes and in non-STEMI treatment pathways, suggesting a need for improved secondary prevention and targeted interventions for this vulnerable population.

24 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
EGEoin Gogarty
Eoin Gogarty
CWCameron Watson
Cameron Watson
MLMaximin Lange
Maximin Lange
BCBen Carter
Ben Carter
SJSameer Jauhar
Sameer Jauhar
FGFiona Gaughran
Fiona Gaughran
Background: Unspecified psychosis-spectrum diagnoses (ICD code F29) are commonly used when the underlying disorder remains uncertain, particularly at first presentation. These diagnoses may persist or later be revised as the clinical picture evolves, yet little is known about their long-term trajectories or implications for treatment and service use in routine mental healthcare. Objectives: To describe the usage and persistence of unspecified non-organic psychosis (F29) and other non-specific diagnoses, and the time to transition to a specific diagnosis. Secondary objectives are to describe temporal trends in their use, identify demographic and clinical characteristics associated with diagnostic persistence, and characterise treatment patterns, service utilisation, mortality, and discharge across diagnostic groups. Methods: We will conduct a retrospective longitudinal cohort study using de-identified electronic health-record data from the South London and Maudsley NHS Foundation Trust (SLaM), accessed through the Clinical Record Interactive Search (CRIS) system, between 1 January 2007 and 31 December 2024. The study population will include patients with an ICD-10 psychosis-spectrum diagnosis (F2x.x), substance induced psychotic disorder (or F1x.5), bipolar disorder or affective disorder with documented psychotic symptoms(F32/3.3). Diagnoses will be classified as specific or non-specific according to their ICD-10 category. Primary analysis will examine time from first F29 diagnosis to first subsequent specific psychosis-spectrum or bipolar diagnosis using Cox proportional hazards regression, with discharge from SLaM, death and administrative end of follow-up treated as censoring events. Associations with diagnostic transition will be examined adjusting for age, sex, ethnicity, area-level deprivation, route of service entry, and calendar period. Secondary competing-risk analysis will estimate the cumulative incidence of diagnostic transition using the Aalen– Johansen estimator, treating discharge and death as competing events. Ethics and Dissemination: CRIS operates under ethical approval from the South Central–Oxford C Research Ethics Committee (23/SC/0257). Project-specific approval was received from the CRIS Oversight Committee as Project 23-095. The study will be reported in accordance with the RECORD extension of the STROBE guidelines. Findings will be disseminated through peer-reviewed publication and will provide evidence on the longitudinal use and refinement of non-specific psychosis-spectrum diagnoses in routine secondary mental healthcare.

22 May 2025 in BMC Digital Health
Verified
Journal Article
Open access
PDF file
MLMaximin Lange
Maximin Lange
EGEoin Gogarty
Eoin Gogarty
MMMeredith Martyn
Meredith Martyn
PBPhilip Braude
Philip Braude
FFFeras Fayez
Feras Fayez
BCBen Carter
Ben Carter
Background: Drug development is lengthy and costly, making drug repurposing an attractive alternative. Identifying repurposing candidates from vast biomedical literature is challenging. Natural language processing (NLP) offers potential for literature-based discovery. We present and evaluate a novel, accessible NLP-based method using the Word2Vec algorithm to identify, test, and validate candidate medications for repurposing, demonstrated by seeking treatments for psychotic disorders. Results: A Word2Vec model trained on 2.3 million PubMed abstracts (2000–2023) identified potential repurposing candidates based on cosine similarity to a known antipsychotic drug. We tested one candidate, a cephalosporin antibiotic, across independent datasets: MIMIC-IV, CRIS, and BRATECA. Cephalosporin antibiotics in MIMIC-IV demonstrated a reduced hazard ratio (aHR) for psychosis hospitalisation overall (0.94, 95% CI: 0.90–0.99) and more substantially for severe mental illness (0.52, 95% CI: 0.45–0.60). However, CRIS showed an increased risk (HR: 3.56, 95% CI: 2.66–4.77). BRATECA lacked suitable diagnostic data for analysis. Conclusions: This methodological framework demonstrates the potential for machine learning approaches to systematically identify drug repurposing candidates, while highlighting population-specific variations in therapeutic effectiveness that warrant caution in translational applications. Our findings should not be interpreted as cephalosporins to be recommended for or against treating psychosis. Our findings merely offer validity to the application of our repurposing methodology, and should serve as a foundation for further investigation rather than direct clinical application.